Uterine leiomyomata and endometrial proliferation in postmenopausal women treated with the anti-oestrogen tamoxifen

Austin Ugwumadu, Kate Harding
In: European Journal of Obstetrics & Gynecology and Reproductive Biology · 1994 · vol. 54(2) , pp. 153–156 · doi:10.1016/0028-2243(94)90258-5 · PMID:8070603 · W2016587661
article OA: closed CC0 ⤵ 3 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-09 ⓘ

This study investigated the effects of tamoxifen on uterine leiomyomata and endometrial proliferation in postmenopausal women.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Two cases of fibroid growth and endometrial proliferation in postmenopausal women on tamoxifen (anti-oestrogen) therapy for breast cancer are described. Oestrogen in association with growth factors may control fibroid growth and differentiation. The possible mechanisms and consequences of tamoxifen-induced fibroid growth are discussed. Oestrogen responsive tissues demonstrate a differential and contrasting response to tamoxifen and caution should be exercised in the expansion of its clinical application. Women on long-term tamoxifen therapy may benefit from ultrasound surveillance of their uterus and endometrium, with biopsy in suspicious cases, as there is a paucity of data on malignant transformation of these benign lesions induced by tamoxifen therapy.

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (4)

Cited by (3)

References (36)

Cited by (3)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK